AlphAIalphai — Financial news for AI agents
SEC EDGARMAY 261 min read$RCKT

Shah Gaurav sold $172K of RCKT

Shah Gaurav (CEO) sold 55,684 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.09 ($0.17M total) on 2026-05-21.

Original reporting
SEC EDGAR · Shah Gaurav
Published May 26, 2026, 11:47 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 11:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$RCKT
Neutral
medium confidence
Mentioned
$RCKT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The disclosure may slightly weigh on sentiment for RCKT traders, but it does not introduce new operational, clinical, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

No context on prior sales cadence, total insider ownership trend, or whether the sale was part of broader personal financial planning.

Relevance 6/10Timing: Immediate (same-day read-through for sentiment), but not a catalyst for fundamentals.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Rocket Pharmaceuticals (RCKT).

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 55,684 shares in an open-market transaction reported on SEC Form 4.

Expected impact

Likely limited, short-lived impact unless follow-on selling accelerates or coincides with other negative news.

Evidence & confidence

This is a routine Form 4 disclosure (no 10b5-1 plan stated) with a modest dollar amount relative to typical market moves; without accompanying company-specific news, directional conviction is low.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide regulatory/clinical developments.

Regional

None indicated; filing is US-based and company-specific.

Global

Low—no international deal, trial, or regulatory action referenced.

Counterpoint

What could challenge this read

The sale could be liquidity-driven (taxes/diversification) and does not necessarily reflect negative expectations.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale by CEO Shah Gaurav.

  • insider
    Shah Gaurav

    CEO who sold 55,684 shares at $3.0860/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 4
$RCKTHighAI 9/10

RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off

Rocket Pharmaceuticals (RCKT) shares fell 22% despite FDA approval of its gene therapy Kresladi for a rare pediatric disorder. The company received a Rare Pediatric Disease Priority Review Voucher. Analysts from Wedbush and LifeSci Capital maintained 'Outperform' ratings, citing the milestone and potential financial benefits. RCKT stock has dropped 53% in the past year.

stocktwits.com2 min
SEP 2
$RCKTMedAI 8/10

Rocket amended complaint alleges UWM targeted Mr. Cooper borrowers

Rocket amended its complaint against UWM, alleging UWM breached agreements by targeting Mr. Cooper borrowers for refinancing, causing prepayment rates 2.5x higher. Rocket claims $100M in damages, citing UWM's initiatives like Refi75 and KEEP. UWM denies allegations, calling them baseless. Rocket acquired Mr. Cooper for $14.2B in 2025.

housingwire.com3 min
AUG 10
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Results of Operations and Financial Condition

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic mic

SEC EDGAR 8-K6 min
AUG 4
$RCKTMed

Rocket points to Danon gene therapy’s safety after Phase II protocol change

Rocket Pharmaceuticals said its RP-A501 Danon disease gene therapy has safely treated three Phase II patients after an FDA-triggered protocol change. The FDA allowed relaunch of NCT06092034 in Aug 2025. Rocket reports no capillary leak syndrome, blood vessel damage, or other serious adverse events since dosing with a recalibrated dose plus rituximab, sirolimus, and corticosteroids.

yahoo.com5 min
AUG 3
$RCKTMed

Why is Rocket Pharmaceuticals stock volatile today?

Investing.com reports Rocket Pharmaceuticals (RCKT) rose 0.6% pre-open after it said the first three patients treated under a revised Phase 2 protocol for RP-A501 Danon disease gene therapy showed no significant safety issues, including no thrombotic microangiopathy or capillary leak syndrome. The FDA lifted the clinical hold in mid-2025. Shares were $3.13 ahead of Aug 6 Q2 2026 earnings.

investing.com3 min
JUN 12
$RCKTMed

ROCKET PHARMACEUTICALS, INC. (RCKT): Completion of Acquisition or Disposition of Assets

ROCKET PHARMACEUTICALS, INC. (RCKT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. false 0001281895 0001281895 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2026 R

SEC EDGAR 8-K2 min